Consolidated and Standalone Financial Results for Quarter and Financial Year ending 31st March,2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Concord Drugs Ltd's board approved audited results for FY25 on May 23, 2025. On a standalone basis, net sales fell to Rs 3,693.21 lakhs from Rs 4,326.07 lakhs in FY24 — a decline of roughly 14.6%. Profit before tax edged up to Rs 64.13 lakhs from Rs 55.84 lakhs, but profit after tax slipped to Rs 29.57 lakhs (from Rs 41.94 lakhs) due to higher tax incidence, leaving EPS flat at Rs 0.42. On a consolidated basis (including subsidiary Proton Remedies Pvt Ltd), revenue was nearly flat at Rs 4,524.46 lakhs and PAT fell to Rs 33.62 lakhs. Total assets grew to Rs 5,858.16 lakhs and equity rose modestly to Rs 3,411.36 lakhs, while operating cash flow remained healthy at Rs 316.31 lakhs. Statutory auditor Pundarikashyam and Associates issued an unmodified opinion but flagged three emphasis-of-matter points, notably Rs 4.14 crore of trade receivables outstanding for over 2 years with no provision for bad debts.
The top-line decline and dip in standalone PAT despite better operating margins suggest margin pressures have been offset by volume weakness. The auditor's emphasis on aged, unprovided receivables is a quality-of-earnings red flag that shareholders should watch, as it could hit profits if eventually written off.